Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucia Tornaghi

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Journal of the National Cancer Institute|November 18, 2004
Development of c-Kit-expressing small-cell lung cancer in a chronic myeloid leukemia patient during imatinib treatmentCarlo Gambacorti-Passerini, Rocco Piazza, Lucia Tornaghi, et al.
Haematologica|June 21, 2006
Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual diseaseAnna Franceschino, Lucia Tornaghi, Rocco Piazza, et al.
Haematologica|February 5, 2008
Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinibAnna Franceschino, Lucia Tornaghi, Valerie Benemacher, et al.
Nature Medicine|January 9, 2007
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'Carlo Gambacorti-Passerini, Carlo Gambacorti, Lucia Tornaghi, et al.
Blood|February 8, 2007
Imatinib concentrations in human milkCarlo B Gambacorti-Passerini, Lucia Tornaghi, Elena Marangon, et al.
Leukemia Research|September 1, 2009
Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemiaStefania Mariani, Lucia Tornaghi, Marianna Sassone, et al.
Blood Cells, Molecules & Diseases|August 16, 2006
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 yearsRocco G Piazza, Vera Magistroni, Anna Franceschino, et al.
Lancet (London, England)|June 13, 2003
Gynaecomastia in men with chronic myeloid leukaemia after imatinibCarlo Gambacorti-Passerini, Lucia Tornaghi, Francesco Cavagnini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patientsCarlo Gambacorti-Passerini, Massimo Zucchetti, Domenico Russo, et al.
Transfusion|July 1, 2005
Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylatePaolo Perseghin, Carlo Gambacorti-Passerini, Lucia Tornaghi, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of the National Cancer Institute|November 18, 2004
Development of c-Kit-expressing small-cell lung cancer in a chronic myeloid leukemia patient during imatinib treatmentCarlo Gambacorti-Passerini, Rocco Piazza, Lucia Tornaghi, et al.
Haematologica|June 21, 2006
Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual diseaseAnna Franceschino, Lucia Tornaghi, Rocco Piazza, et al.
Haematologica|February 5, 2008
Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinibAnna Franceschino, Lucia Tornaghi, Valerie Benemacher, et al.
Nature Medicine|January 9, 2007
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'Carlo Gambacorti-Passerini, Carlo Gambacorti, Lucia Tornaghi, et al.
Blood|February 8, 2007
Imatinib concentrations in human milkCarlo B Gambacorti-Passerini, Lucia Tornaghi, Elena Marangon, et al.
Leukemia Research|September 1, 2009
Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemiaStefania Mariani, Lucia Tornaghi, Marianna Sassone, et al.
Blood Cells, Molecules & Diseases|August 16, 2006
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 yearsRocco G Piazza, Vera Magistroni, Anna Franceschino, et al.
Lancet (London, England)|June 13, 2003
Gynaecomastia in men with chronic myeloid leukaemia after imatinibCarlo Gambacorti-Passerini, Lucia Tornaghi, Francesco Cavagnini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patientsCarlo Gambacorti-Passerini, Massimo Zucchetti, Domenico Russo, et al.
Transfusion|July 1, 2005
Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylatePaolo Perseghin, Carlo Gambacorti-Passerini, Lucia Tornaghi, et al.
Pageof 2